Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)

Carlo Di Mario, Leonardo Bolognese, Luc Maillard, Dariusz Dudek, Giampaolo Gambarati, Antonio Manari, Vincenzo Guiducci, Giampiero Patrizi, Luigi Cesare Rusconi, Giancarlo Piovaccari, Agnes Ricard Hibon, Vanessa Belpomme, Ciro Indolfi, Zoran Olivari, Giuseppe Steffenino, Krzysztof Zmudka, Flavio Airoldi, Rita Panzarasa, Marcus Flather, Philippe Gabriel Steg

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)


Most patients with acute myocardial infarction (AMI) are admitted to hospitals without percutaneous transluminal coronary angioplasty (PTCA) facilities or are initially managed in a prehospital mobile unit. Thrombolysis remains the most readily available reperfusion treatment in those settings, but the optimal subsequent strategy in those patients is unclear. If a mechanical recanalization is likely to be performed in an emergency, it is probably desirable that the patient receives abciximab, the glycoprotein IIb/IIIa antagonist with the strongest evidence of benefit for angioplasty in AMI.
Original languageEnglish
Pages (from-to)378-85
Number of pages8
JournalAmerican Heart Journal
Issue number3
Publication statusPublished - Sep 2004


  • Antibodies, Monoclonal
  • Cost-Benefit Analysis
  • Drug Therapy, Combination
  • Emergency Medical Services
  • Humans
  • Immunoglobulin Fab Fragments
  • Myocardial Infarction
  • Plasminogen Activators
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Prospective Studies
  • Recombinant Proteins
  • Recurrence
  • Stents
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator
  • Treatment Outcome

Cite this